Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10 EUR | +1.01% | -13.04% | -42.53% |
05-09 | DA Davidson Adjusts Nu Skin Enterprises' Price Target to $12.50 From $15.50, Keeps Neutral Rating | MT |
05-08 | Transcript : Nu Skin Enterprises, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- With a P/E ratio at 11.58 for the current year and 7.37 for next year, earnings multiples are highly attractive compared with competitors.
- The stock, which is currently worth 2024 to 0.4 times its sales, is clearly overvalued in comparison with peers.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-42.53% | 523M | - | ||
+14.34% | 137B | B- | ||
+21.74% | 79.62B | A+ | ||
-6.12% | 69.77B | A- | ||
-27.25% | 38.15B | B+ | ||
-15.56% | 34.81B | - | ||
+0.63% | 32.75B | B- | ||
+8.56% | 17.97B | A- | ||
+22.39% | 16.88B | B | ||
+9.15% | 12.77B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NUS Stock
- NUS Stock
- Ratings Nu Skin Enterprises, Inc.